Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)
Have questions about this legislation?
Our AI can explain provisions, analyze impacts, and answer questions in plain English.
Already have an account? Sign in
Make your voice heard on this bill.
Upgrade to Plus to generate an AI letter and send it to your House representative.
Get an instant AI-powered breakdown of this bill — what it does, who it affects, and what matters.
Create free accountAlready have an account? Sign in
Hear what historical figures and modern thinkers might say about this legislation.
Founding Fathers
Historical Leaders
Modern Thinkers
See how Jefferson, Churchill, or Einstein would react to this bill.
Create free accountAlready have an account? Sign in